Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Göster/ Aç
Erişim
info:eu-repo/semantics/restrictedAccessTarih
2019Yazar
Kılıçkap, SaadettinBuğdaycı Basal, Fatma
Demirkazık, Ahmet
Gürsoy, Pınar
Demirci, Ufuk
Erman, Mustafa
Yumuk, Fulden
Çay Şenler, Filiz
Çakar, Burcu
Çiçin, İrfan
Öztürk, Akın
Coşkun, Hasan Şenol
Çubukçu, Erdem
Işıkdoğan, Abdurrahman
Ölmez, Ömer Fatih
Tatlı, Ali Murat
Karaağaç, Mehmet Onur
Sakalar, Teoman
Eralp, Yeşim
Korkmaz, Taner
Üst veri
Tüm öğe kaydını gösterKünye
Kılıçkap, S., Buğdaycı Basal, F., Demirkazık, A., Gürsoy, P., Demirci, U., Erman, M. ... Korkmaz, T. (2019). Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?44th Congress of the European-Society-for-Medical-Oncology (ESMO) içinde (637-637. ss.). Barcelona, Spain, September 27-October 01, 2019.Özet
Background: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALKþ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALKþpatients who have Ple-I/E. Methods: In this multicenter study, patients with ALKþ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALKþpatients with NSCLC. Results: Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p¼0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p¼0.541). The rate of smokers was 43.4% (n¼157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p¼0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALKþpatients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p¼0.008; 19.1% vs 4.8%, p¼0.002; 20.6% vs 8.9%, p¼0.003). The median PFS was longer in ALKþ patients who have Ple-I/E 18.7 vs 10.6 months, p¼0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALKþpatients who have pleural involvement/infusion 44.6 vs 22.6 months, p¼0.051). The 1-, 2- and 3- year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement. Conclusions: Brain, liver and bone metastases are lower in ALKþpatients with Ple-I/E. Presentation with Ple-I/E in patients with ALKþ NSCLC is associated with longer overall and progression-free survival. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
WoS Q Kategorisi
Q1Kaynak
44th Congress of the European-Society-for-Medical-Oncology (ESMO)Cilt
30Sayı
Supplement: 5Koleksiyonlar
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6717]